<p></p><p>In
the middle of SARS-CoV-2 pandemic, dengue virus (DENV) is giving a silent
warning as the season approaches nearer. There is no specific antiviral against
DENV for use in the clinics. Thus, considering these facts we can potentially
face both these viruses together increasing the clinical burden. The search for
anti-viral drugs against SARS-CoV-2 is in full swing and repurposing of already
‘in-use’ drugs against other diseases or COVID-19 has drawn significant
attention. Earlier we had reported few FDA approved anti-viral and
anti-microbial drugs that could be tested for binding with SARS-CoV-2
nucleocapsid N terminal domain. We explored the possibility of interactions of
the drugs screened for SARS-CoV2 with Dengue virus capsid protein. We report five
FDA approved drugs that were seen to be docking onto the SARS-CoV-2
nucleocapsid RNA binding domain, also docking well with DENV capsid protein on
the RNA binding site and/or the capsid’s membrane fusion domain. Thus, the present
study proposes these five drugs as common antiviral candidates against both
SARS-CoV-2 and DENV although the <i>in silico</i> study is subject to further
validations.</p><br><p></p>
Dengue Virus Capsid Protein Dynamics Reveals Spatially Heterogeneous Motion in Live-Infected-Cells
